Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by WalkOverTheStrton Apr 25, 2023 3:32pm
80 Views
Post# 35413097

GA letter that corresponds to PR today

GA letter that corresponds to PR today Attached is a news release which has been released. Here are some background points: 1. The AEPC is a major event in our 2023 schedule of conferences and the presentation by Dr. Laser is the first podium presentation we have had in some years. 2. Dr. Laser has been a strong champion for the VMS products and has published a number of excellent research studies such as: "Real-time 3D-echocardiography of the right ventricle-paediatric reference values for right ventricular volumes using knowledge-based reconstruction: a multicentre study" Quant Imaging Med Surg. 2021;11(7):2905-2917. wherein 74.5% of cases could be analyzed. This was a major achievement and showed real-time 3D-echocardiography (also known as 4D) with VMS+ analysis could be used as a clinical tool. 3. The booth is always filled with people after such a presentation and so we will have a full team there to collect contact information and follow up after the event. 4. Germany, where Dr. Laser is a key opinion leader, is an excellent market for us and AngioPro our European distributor, who is based in Germany, has now hired an application specialist to do on-site demonstrations, which are critical to the decision to adopt the VMS+ products. Thank you for your continued interest and support as we go forward to improve cardiac diagnostics for everyone everywhere and especially for children.
<< Previous
Bullboard Posts
Next >>